Introduction: The rapid development of the pharmaceutical industry has increased the need to assess and monitor the use of medicines. Thus, necessitates the importance of monitoring the appropriate use of medicines including antimicrobials. Objective: Pharmacoeconomic analysis of pharmacotherapy in the nephrology department at a multidisciplinary hospital. Methods: The study is a retrospective analysis of medicine use and expenditure. The study utilized the ABC-VEN analysis of medical use and the WHO-AWaRe-2021 analysis of antibiotic use, to determine the prescription and financial trends of the nephrology department (30 beds) of a multidisciplinary regional hospital (total 844 beds) in Turkestan, Kazakhstan 2018-2021. Results: The analyzed costs of drugs included 116 international nonproprietary names prescribed to patients from the nephrology department during the study period. In total, pharmacotherapy costs increased by 52.6% in 2021 compared to 2018. Five INN drugs were purchased without their inclusion in the Kazakhstan National Medicinal Formulary, such as atropine sulfate, sodium bicarbonate, sodium chloride (crystalline salt), nitroxoline, and nitrofural. The pharmacoeconomics analysis of antibiotics usage for 2018-2021 showed a sharp increase in the%age of costs. Conclusion: The study showed an increase in funding for pharmacotherapy in the department of nephrology, which increases the availability of medicines. However, the trend in prescribing drugs with poor evidence base level, and the increase in the proportion of antibiotic prescription, require immediate intervention including the utilization of clinical pharmacy services for regular assessment of the pharmacoeconomic feasibility of antibiotic therapy. This will improve the quality of medical care and reduce the financial costs.
25 February 2024 in Journal of Clinical Medicine of Kazakhstan
Brief Description: The investigation of glomerular disease prevalence is vital for comprehending chronic kidney disease development, particularly in regions like Kazakhstan and Central Asia, where confirming data is lacking. This study focuses on the epidemiology of glomerular diseases, utilizing registered cases of glomerular diseases in the national electronic health system. Research Methods: The research involves data from 31,421 patients recorded in the Unified National Electronic Healthcare System database, covering glomerular diseases with ICD-10 codes N01-N08 between 2014 and 2019. Descriptive statistics encompass demographic characteristics, all-cause mortality, prevalence and incidence rates, and comorbidities. Results: Results reveal a substantial rise in diagnosed cases from 7,756 (2014) to 30,686 (2019), with corresponding all-cause mortality increasing from 254 to 1,025. Also, new cases went up from 4,875 (2014) to 6,320 (2019). Over the period, 51% were women, 49% were men, and 67% were of Kazakh ethnicity. Russian nationality constituted 16%, and other ethnic groups comprised 17%. Diabetes mellitus emerged as the primary comorbidity, associated with 20% of cases. Conclusion: This is the first descriptive study in Central Asia scrutinizing the epidemiology of patients with glomerular diseases (ICD-10 code N01-N08) using administrative healthcare data in Kazakhstan. The findings indicate an escalation in prevalence and mortality, coupled with a gradual increase in incidence among glomerular disease patients from 2014 to 2019. The study underscores the pivotal role of diabetes mellitus as a predominant comorbidity in this context.